{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-034778","form_type":"8-K","ticker":"ACOG","cik":"0001655923","company_name":"Alpha Cognition Inc.","filed_at":"2026-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.783574+00:00","generated_at":"2026-05-15T08:50:43.354510+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Alpha Cognition FY2025 revenue $10.2M, net loss $20.7M; ZUNVEYL bottles up 62% QoQ","bullets":["FY2025 total revenue $10.2M: ZUNVEYL net product revenue $6.8M + licensing $3.4M.","Q4 ZUNVEYL net product revenue $2.5M; 4,941 bottles dispensed (+62% QoQ); December strongest month.","Net loss $20.7M vs $14.8M in 2024; operating loss $22.7M vs $12.0M in 2024.","Cash $66.0M at year-end; expects ~2-year runway after $40M capital raise in Oct 2025.","Executed second national PBM contract, now covering two of four major long-term care PBMs."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-034778","json":"https://secwatch.observer/filing/0001213900-26-034778.json","markdown":"https://secwatch.observer/filing/0001213900-26-034778.md","text":"https://secwatch.observer/filing/0001213900-26-034778.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655923/000121390026034778/0001213900-26-034778-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655923/000121390026034778/ea0283622-8k_alpha.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:50:43.354510+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1eeb06acfafb8a5dee502eb2d69244818c289b04","claim":"Alpha Cognition Inc. reported the year ended December 31, 2025 results: revenue $10.2 million, net income $20.7 million.","evidence_excerpt":"Full Year Fiscal 2025 Financial Results ● Revenues: ZUNVEYL net product revenues were $6.8 million, and licensing revenue totaled $3.4 million, for a combined total of $10.2 million for the year ended December 31, 2025. ● Research & Development: Expenses were $1.9 million, compared to $3.9 million for fiscal year 2024 as the Company transitioned to commercial stage. ● Selling, General & Administrative : Expenses were $29.1 million, up from $8.0 million in 2024, reflecting increased commercial investment in personnel and infrastructure. ● Operating Loss: $22.7 million, compared to $12.0 million in 2024. ● Net Loss: $20.7 million, compared to $14.8 million in 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1655923/000121390026034778/0001213900-26-034778-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Revenue","value":"$10.2 million"},{"label":"Net income","value":"$20.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"76fd06a58260ce7fe55633d01ee58c5323fbb4b1","claim":"Alpha Cognition Inc. reported the fourth quarter ended December 31, 2025 results: revenue $2.5 million.","evidence_excerpt":"Net ZUNVEYL Revenue: Generated approximately $2.5 million in net product revenue in the fourth quarter of 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1655923/000121390026034778/0001213900-26-034778-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2025"},{"label":"Revenue","value":"$2.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}